Jade Logger

Ms. Jade Logger

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
RAR. E. Aarnoutse
R. E. Aarnoutse
GKG. S. Kibiki
G. S. Kibiki
KRK. Reither
K. Reither
HSH. H. Semvua
H. H. Semvua
FHF. Haraka
F. Haraka
MBM. J. Boeree
M. J. Boeree
In a multiple-dose-ranging trial, we previously evaluated higher doses of rifampin in patients for 2 weeks. The objectives of the current study were to administer higher doses of rifampin for a longer period to compare the pharmacokinetics, safety/tolerability, and bacteriological activity of such regimens. In a double-blind, randomized, placebo-controlled, phase II clinical trial, 150 Tanzanian patients with tuberculosis (TB) were randomized to receive either 600 mg (approximately 10 mg/kg of body weight), 900 mg, or 1,200 mg rifampin combined with standard doses of isoniazid, pyrazinamide, and ethambutol administered daily for 2 months. Intensive pharmacokinetic sampling occurred in 63 patients after 6 weeks of treatment, and safety/tolerability was assessed. The bacteriological response was assessed by culture conversion in liquid and solid media. Geometric mean total exposures (area under the concentration-versus-time curve up to 24 h after the dose) were 24.6, 50.8, and 76.1 mg · h/liter in the 600-mg, 900-mg, and 1,200-mg groups, respectively, reflecting a nonlinear increase in exposure with the dose ( P < 0.001). Grade 3 adverse events occurred in only 2 patients in the 600-mg arm, 4 patients in the 900-mg arm, and 5 patients in the 1,200-mg arm. No significant differences in the bacteriological response were observed. Higher daily doses of rifampin (900 and 1,200 mg) resulted in a more than proportional increase in rifampin exposure in plasma and were safe and well tolerated when combined with other first-line anti-TB drugs for 2 months, but they did not result in improved bacteriological responses in patients with pulmonary TB. These findings have warranted evaluation of even higher doses of rifampin in follow-up trials. (This study has been registered at ClinicalTrials.gov under identifier NCT00760149.)

1 October 2020 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
JLJade Logger
Jade Logger
JOJill I. Olydam
Jill I. Olydam
RDRieke J.B. Driessen
Rieke J.B. Driessen
Flushing and erythema are frequent skin symptoms in rosacea. As their adequate treatment remains a clinical challenge, new treatment options are explored, such as oral β-blockers. To evaluate the efficacy of oral β-blockers for rosacea-associated facial flushing and erythema. PubMed, EMBASE, Web of Science, and Cochrane Library were systematically searched, including studies providing original data on the efficacy of oral β-blockers in rosacea patients with facial flushing and/or persistent erythema. Risk of bias was assessed using the Cochrane Risk of Bias tool, Newcastle-Ottawa scale, and Quality in Prognosis Studies tool. Nine studies evaluating the use of carvedilol, propranolol, nadolol, and β-blockers in general were included. Articles studying carvedilol and propranolol showed a large reduction of erythema and flushing during treatment with a rapid onset of symptom control. Bradycardia and hypotension were the most commonly described adverse events. Most studies had a retrospective design with a small sample size, and outcome measurement was often subjective. Oral β-blockers could be an effective treatment option for rosacea patients with facial erythema and flushing that does not respond to conventional therapy. Larger prospective trials with objective outcome assessment are needed to validate the promising results of these studies.

14 June 2020 in Skin Research and Technology
Verified
Journal Article
Open access
PDF file
JLJade Logger
Jade Logger
EJElke M. G. J. de Jong
Elke M. G. J. de Jong
RDRieke J. B. Driessen
Rieke J. B. Driessen
Piet van ErpPiet van Erp
Piet van Erp
Background: Facial erythema is a common symptom in rosacea. To overcome subjectivity in scoring erythema severity, objective redness quantification is desirable. This study evaluated an image‐based erythema quantification tool to monitor facial erythema in rosacea patients during treatment and compared these values to clinical scores.Materials and Methods: Twenty‐one rosacea patients were treated with topical ivermectin for 16 weeks. Clinical erythema scores and clinical photographs were taken at week 0, 6, 16 and 28. Using ImageJ, RGB images were split into red, green and blue channels to measure the green/red ratio of lesional skin compared with a green sticker. With CIELAB colour space, a* (indicating colour from green to red) of a lesional and non‐lesional facial site was measured, calculating ∆a*. Interobserver concordance and correlation between quantitative and clinical erythema values were determined.Results: Treatment resulted in reduction of clinical erythema scores. No significant changes in red/green ratios were measured. Lesional a* and ∆a* significantly decreased from baseline to week 16 and 28 (P < .05). A weak correlation existed between clinical scores and lesional a* (Rs = 0.37), and between clinical scores and ∆a* (Rs = 0.30), with a clear trend towards higher a* and ∆a* for higher clinical scores. Interobserver correlation was high (R2 = 0.82).Conclusion: ImageJ is a simple, rapid, objective and reproducible tool to monitor erythema in rosacea patients during treatment. The photographs allow retrospective analysis, evaluation of large and small lesions, and discrimination of subtle redness differences. We recommend using lesional a* to monitor erythema of inflammatory dermatoses in clinical practice.

23 May 2019 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
JLJade Logger
Jade Logger
FVF.M.C. Vries
F.M.C. Vries
Piet van ErpPiet van Erp
Piet van Erp
EJE.M.G.J. Jong
E.M.G.J. Jong
MPM. Peppelman
M. Peppelman
RDR. J. B. Driessen
R. J. B. Driessen
Background Rosacea assessment and therapy monitoring can be challenging to standardize, as most clinical evaluation systems are prone to interobserver variability and not always validated. Objective, reliable and preferably non‐invasive measurement tools are therefore needed. Objectives To give insight into available non‐invasive imaging techniques and biophysical methods in rosacea by performing a systematic review. Methods PubMed, EMBASE, Cochrane and Web of Science databases were searched until 1 September 2018 in accordance with PRISMA guidelines, identifying studies providing original data about objective non‐invasive imaging and/or biophysical skin measurement techniques for diagnosis, assessing severity or therapy monitoring of adult patients with cutaneous facial rosacea. Risk of bias of included articles was assessed with the Cochrane Risk of Bias tool, Newcastle Ottawa Scale and Quality in Prognosis Studies tool. Results A total of 78 studies was included, describing 14 imaging and biophysical methods. Widespread information about (sub)surface cutaneous morphology and functionality was obtained. Methodological study quality was relatively low and interstudy outcome variability was large. Several tools show promising value in research settings; for treatment follow‐up, Demodex mites are countable with reflectance confocal microscopy, spectrometry can quantify erythema, and rosacea severity could be objectified with skin hydration and transepidermal water loss measurements. Conclusions This systematic review describes the spectrum of non‐invasive imaging and biophysical methods in rosacea assessment, giving multifaceted information about structure and properties of rosacea skin, especially useful for research purposes. Larger studies with good methodological quality are needed to create validated protocols for further implementation into research.

3 January 2019 in Skin Research and Technology
Verified
Journal Article
Open access
PDF file
JLJade Logger
Jade Logger
CMChristina U. Münchhoff
Christina U. Münchhoff
JOJill I. Olydam
Jill I. Olydam
MPMalou Peppelman
Malou Peppelman
Piet van ErpPiet van Erp
Piet van Erp
Background: This pilot study aimed to investigate the anatomical site variation of water content of the stratum corneum (SC) on the body by measuring skin capacitance with the Epsilon, a new generation corneometer with multiple sensors. Secondly, values of the Epsilon were compared to values measured by conventional single sensor corneometers.Methods: The hydration status of SC was measured in 15 healthy Caucasian volunteers with the Epsilon at five body sites (cheek, lower forearm, mid‐calf, lower back and abdomen). Transepidermal water loss (TEWL) was measured with the Aquaflux to get more insight into the condition of the skin barrier. A literature search was performed to compare Epsilon values with conventional corneometers.Results: The tested anatomical locations showed significant differences in water content (P < 0.001) with large interindividual variations; highest values were found in the cheek (11.64ε) and lowest values in the mid‐calf (4.43ε). No correlation between water content and TEWL was found. In general, Epsilon values were lower compared to values of conventional corneometers, with a similar trend.Conclusion: This pilot study showed significant variations in water content at different skin locations measured by the Epsilon. Moreover, the Epsilon measured consistent lower values compared to single sensor corneometers. Further validation of the device is recommended.

15 March 2019 in Cosmetics
Verified
Journal Article
Open access
PDF file
JLJade Logger
Jade Logger
JOJill Olydam
Jill Olydam
WWWietske Woliner-Van der Weg
Wietske Woliner-Van der Weg
Piet van ErpPiet van Erp
Piet van Erp
The epidermal barrier function is disrupted in various inflammatory skin diseases. Accurate methods to measure skin barrier function are needed to assess the effect of therapeutic agents. Therefore, we developed a noninvasive multiparametric approach to measure four different parameters regarding the skin barrier. In the current pilot study, we evaluate this method in 14 healthy volunteers. We assessed erythema, transepidermal water loss (TEWL), water content, and epidermal thickness at both cheeks before and 30 min after application of Lanette and Vaseline-Lanette cream. For this, we used spectrophotometry, the Aquaflux device, the Epsilon device, and reflection confocal microscopy, respectively. Stratum corneum (SC) thickness was significantly increased after application of both creams (p < 0.05), and this increase was larger after Lanette cream compared to after Vaseline-Lanette cream (p = 0.035). Erythema, TEWL, and water content did not significantly change after cream application. Our multiparametric approach is promising and offers a feasible and practical way to quickly obtain multifaceted information about skin barrier function. Further exploration of this approach after prolonged use of cream and in conditions of disrupted skin barrier are recommended areas for future research.